Last update 08 May 2025

TY-1091

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
RET
Action
modulators
Mechanism
RET modulators(Tyrosine-protein kinase receptor RET modulators)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseRespiratory Diseases+ [1]
Active Indication
Papillary thyroid cancerAdvanced Malignant Solid NeoplasmRET fusion-positive Non-Small Cell Lung Cancer+ [4]
Inactive Indication-
Originator Organization
TYK Medicines, Inc.TYK Medicines, Inc.
Active Organization
TYK Medicines, Inc.TYK Medicines, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with TY-1091
NCT05675605
/ RecruitingPhase 1/2
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET Alterations
CTR20223304
/ RecruitingPhase 1/2
一项评价选择性RET抑制剂TY-1091胶囊在晚期实体瘤患者中安全性、耐受性、药代动力学及有效性的I/II期临床研究
[Translation] A Phase I/II clinical study evaluating the safety, tolerability, pharmacokinetics and efficacy of the selective RET inhibitor TY-1091 capsule in patients with advanced solid tumors
100 Clinical Results associated with TY-1091
Login to view more data
100 Translational Medicine associated with TY-1091
Login to view more data
100 Patents (Medical) associated with TY-1091
Login to view more data
100 Deals associated with TY-1091
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Papillary thyroid cancerPhase 2
China
TYK Medicines, Inc.TYK Medicines, Inc.
24 Apr 2023
Advanced Malignant Solid NeoplasmPhase 2
China
TYK Medicines, Inc.TYK Medicines, Inc.
17 Apr 2023
RET fusion-positive Non-Small Cell Lung CancerPhase 2
China
TYK Medicines, Inc.TYK Medicines, Inc.
17 Apr 2023
RET mutation Solid TumorsPhase 2
China
TYK Medicines, Inc.TYK Medicines, Inc.
17 Apr 2023
RET Mutation-Positive Medullary Thyroid CancerPhase 2
China
TYK Medicines, Inc.TYK Medicines, Inc.
17 Apr 2023
RET fusion-positive Solid TumorsPhase 1
China
TYK Medicines, Inc.TYK Medicines, Inc.
-
NeoplasmsIND Application
United States
TYK Medicines, Inc.TYK Medicines, Inc.
30 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free